TSHA

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.

Wall Street analysts forecast TSHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TSHA is 10.50 USD with a low forecast of 5.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Taysha Gene Therapies Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

Taysha Gene Therapies Inc. EPS for the last quarter amounts to -0.09 USD, decreased -10.00 % YoY.

Taysha Gene Therapies Inc (TSHA) has 73 emplpoyees as of December 15 2025.

Today TSHA has the market capitalization of 1.59B USD.